Overview

Safety of LEO 43204 for Actinic Keratosis Applied on Face/Chest, Scalp and Trunk/Extremities, Respectively

Status:
Completed
Trial end date:
2015-08-01
Target enrollment:
Participant gender:
Summary
The objective of the trial is to investigate the Safety of LEO 43204 0.018%, 0.037% and 0.1% for actinic keratosis applied once daily for three consecutive days on face/chest, scalp and trunk/extremities, respectively.
Phase:
Phase 2
Details
Lead Sponsor:
LEO Pharma